Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 13;149(7):498-509.
doi: 10.1161/CIRCULATIONAHA.123.065600. Epub 2023 Nov 14.

Effect of Mavacamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy: Insights From EXPLORER-HCM

Sharon Cresci  1   2 , Richard G Bach  1 , Sara Saberi  3 , Anjali T Owens  4 , John A Spertus  5 , Sheila M Hegde  6 , Neal K Lakdawala  6 , Ester Kim Nilles  7 , Daniel M Wojdyla  7 , Amy J Sehnert  8 , Andrew Wang  9
Affiliations

Effect of Mavacamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy: Insights From EXPLORER-HCM

Sharon Cresci et al. Circulation. .

Abstract

Background: Compared with men, women with hypertrophic cardiomyopathy (HCM) have a higher incidence of heart failure and worse outcomes. We investigated baseline clinical and echocardiographic characteristics and response to mavacamten among women compared with men in the EXPLORER-HCM study (Clinical Study to Evaluate Mavacamten [MYK-461] in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy).

Methods: A prespecified post hoc analysis of sex from the blinded, randomized EXPLORER-HCM trial of mavacamten versus placebo in symptomatic patients with obstructive HCM was performed. Baseline characteristics were compared with t tests for continuous variables (expressed as mean values) and χ2 tests for categorical variables. Prespecified primary, secondary, and exploratory end points and echocardiographic measurements from baseline to end of treatment (week 30) were analyzed with ANCOVA for continuous end points and a generalized linear model with binomial distribution for binary end points, with adjustment for each outcome's baseline value, New York Heart Association class, β-blocker use, and ergometer type.

Results: At baseline, women (n=102) were older (62 years versus 56 years; P<0.0001), had lower peak oxygen consumption (16.7 mL·kg-1·min-1 versus 21.3 mL·kg-1·min-1; P<0.0001), were more likely to be assigned New York Heart Association class III (42% versus 17%; P<0.0001), had worse health status (Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score 64 versus 75; P<0.0001), and had higher baseline plasma NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels (1704 ng/L versus 990 ng/L; P=0.004) than men (n=149). After 30 weeks of mavacamten treatment, similar improvements were observed in women and men in the primary composite end point (percentage difference on mavacamten versus placebo, 22% versus 19%, respectively; P=0.759) and in the secondary end points of change in postexercise left ventricular outflow tract gradient (-42.4 mm Hg versus -33.6 mm Hg; P=0.348), change in peak oxygen consumption (1.2 mL·kg-1·min-1 versus 1.6 mL·kg-1·min-1; P=0.633), and percentage achieving ≥1 New York Heart Association class improvement (41% versus 28%; P=0.254). However, women had greater improvement in health status (Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score 14.8 versus 6.1; P=0.026) and in the exploratory end point of NT-proBNP levels (-1322 ng/L versus -649 ng/L; P=0.0008).

Conclusions: Although at baseline women with symptomatic obstructive HCM enrolled in EXPLORER-HCM were older and had worse heart failure and health status than men, treatment with mavacamten resulted in similar improvements in the primary and most secondary EXPLORER-HCM end points and greater improvements in health status and NT-proBNP.

Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03470545.

Keywords: clinical study; heart failure.

PubMed Disclaimer

Conflict of interest statement

Disclosures Dr Cresci reports institution research funding for clinical trial from Imbria Pharmaceuticals and serving on the Data Monitoring Committee for Cytokinetics. Dr Bach reports institution research funding for clinical trials from BMS and Cytokinetics. Dr Saberi reports consulting for Cytokinetics and BMS. Dr Owens reports consulting for BMS, Cytokinetics, Pfizer, Tenaya, Renovacor, Stealth, Edgewise, Lexicon, and Biomarin. Dr Spertus reports consulting on patient-reported outcomes and evidence evaluation for Alnylam, AstraZeneca, Bayer, Merck, Janssen, BMS, Edwards, Kineksia, 4DT Medical, Terumo, Cytokinetics, Imbria, and United Healthcare; receiving research grants from BMS, Abbott Vascular, and Janssen; holding copyright to the Seattle Angina Questionnaire, KCCQ, and Peripheral Artery Questionnaire; and serving on the Board of Directors for Blue Cross Blue Shield of Kansas City. Dr Hegde reports fees paid to institution for core laboratory services from Myokardia/BMS. Dr Lakdawala reports consulting for BMS, Cytokinetics, Tenaya, Pfizer, and Akros and receiving research support from BMS and Pfizer. Dr Nilles and D.M. Wojdyla report no conflicts. Dr Sehnert is an employee of BMS and owns stock/stock grants from BMS. Dr Wang reports research grant to institution from BMS and Cytokinetics and serving on the Advisory Board (consultant) for BMS, Cytokinetics, and BioMarin and speakers’ bureau for BMS.

Figures

Figure 1.
Figure 1.. Mean Valsalva-induced Left Ventricular Outflow Tract Gradients Across Study Visits by Treatment and Sex.
Red lines represent women. Blue lines represent men. Solid lines show values for those treated with mavacamten. Dashed lines show values for those treated with placebo. P-values of differences between treatment and placebo within sex subgroup at each visit are provided. Error bars are 95% CI.
Figure 2.
Figure 2.. Mean KCCQ-CS Scores Across Study Visits by Treatment and Sex.
Red lines represent women. Blue lines represent men. Solid lines show values for those treated with mavacamten. Dashed lines show values for those treated with placebo. P-values of differences between treatment and placebo within sex subgroup at each visit are provided. Error bars are 95% CI.
Figure 3.
Figure 3.. Geometric Mean NT-proBNP Levels Across Study Visits by Treatment and Sex.
Red lines represent women. Blue lines represent men. Solid lines show values for those treated with mavacamten. Dashed lines show values for those treated with placebo. Values are displayed as geometric means. P-values of differences between treatment and placebo within sex subgroup at each visit are provided. Error bars are 95% CI.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, Evanovich LL, Hung J, Joglar JA, Kantor P, et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2020;142:e533–e557. - PubMed
    1. Maron BJ. Clinical Course and Management of Hypertrophic Cardiomyopathy. N Engl J Med. 2018;379:655–668. - PubMed
    1. Semsarian C, Ingles J, Maron MS and Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015;65:1249–1254. - PubMed
    1. Maron MS, Hellawell JL, Lucove JC, Farzaneh-Far R and Olivotto I. Occurrence of Clinically Diagnosed Hypertrophic Cardiomyopathy in the United States. Am J Cardiol. 2016;117:1651–1654. - PubMed
    1. Maron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, Losi MA, Cecchi F and Maron BJ. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med. 2003;348:295–303. - PubMed

Publication types

Associated data